Area of research
Hematology · Internal Medicine
Research interest
Research interests include Platelet Disorders and Treatments, Blood Coagulation and Thrombosis Mechanisms, Venous Thromboembolism Diagnosis and Management, and Heparin-Induced Thrombocytopenia and Thrombosis.
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF.
Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges.
2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management.
Updated recommendations for warfarin reversal in the setting of four-factor prothrombin complex concentrate.
Enhanced α2-3-linked sialylation determines the extended half-life of CHO-rVWF.
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH
Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH.
Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies.
Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1.
Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis.
Low von Willebrand factor-unraveling an enigma wrapped in a conundrum.
Examining variability in the diagnosis and management of people with bleeding disorders of unknown cause: communication from the ISTH SSC Subcommittee on von Willebrand Factor.
Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress.
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Type 1 VWD classification revisited: novel insights from combined analysis of the LoVIC and WiN studies
Isatuximab plus carfilzomib and dexamethasone in patients with early <i>versus</i> late relapsed multiple myeloma: IKEMA subgroup analysis
Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19.
Low von Willebrand Disease: A Bleeding Disorder of Unknown Cause?
VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.
Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH).